OrbiMed is a global healthcare specialist investor that backs companies across the full healthcare lifecycle, from incubation and seed through public crossover, growth, and non-dilutive royalty/credit financings. The firm is known for deep scientific and commercial diligence, a willingness to lead and take board seats, and flexible capital deployment across biopharma, devices, diagnostics/tools, and tech-enabled healthcare services.
Evaluation weights
How much weight this firm places on each dimension. Totals 100%.
Revenue, growth, and unit economics
Size, timing, and competitive landscape
Founder experience and execution ability
Differentiation and technical quality
- Bias toward healthcare opportunities where specialist diligence creates an edge
- Preference for lead positions with governance influence
- Willingness to fund early risk if scientific conviction is high
- Stronger interest in flexible financing structures when cash flows are durable
Pitch difficulty
How hard it is to get a meeting and close funding from this firm.
- Funded / yr
- 57Deals closed in a typical year.
- Led / yr
- 19Rounds led in the last 12 months.
- Pitches / yr
- ~30992Decks reviewed in a typical year.
- Acceptance rate
- 0.2%Share of pitches that get funded.
Estimated — public data is not fully disclosed.
Why it's hard
- Deep specialist diligence on science, clinical evidence, and management
- Focus on category-defining healthcare innovation rather than incremental products
- Frequent preference to lead rounds and take board seats
- Low tolerance for weak data, unclear regulatory pathways, or governance issues
OrbiMed is highly selective because it is a specialist healthcare investor that performs deep domain diligence, often leads rounds, and holds a high bar for scientific quality, regulatory clarity, management strength, and governance. Its broad stage coverage does not make it easy to access; rather, it reflects the firm's ability to choose only the best-fit healthcare opportunities across many financing types.
Green flags
What drives a yes for this firm.
- High-quality, reproducible science or technical evidence validated through deep diligence
- A credible management team capable of navigating development, regulation, and commercialization
- Clear regulatory pathway with identifiable value-inflection milestones
- Strong commercial rationale, including workflow fit or scalable go-to-market design
- Ability for OrbiMed to lead, influence governance, and support the company across multiple financings
Red flags
What kills deals and gets a fast no.
- Irreproducible science or overstated technical claims
- Ambiguous regulatory strategy or unrealistic development timelines
- Weak governance, poor incentive alignment, or inability to support board-level oversight
- Commercial model with unclear reimbursement, buyer adoption, or workflow fit
- Raising a financing structure that does not match the company’s maturity or risk profile
How to win
Patterns that lead to successful pitches.
- Show a rigorous data package tailored to healthcare specialists, not generalist investors
- Present a crisp regulatory and milestone roadmap with clear value-inflection points
- Demonstrate why the team can execute through the next phase of development and commercialization
- For diagnostics/digital health, prove workflow integration and clinical utility with real users or customers
- For later-stage opportunities, emphasize revenue durability, cash-flow visibility, and financing fit
Fund strategy & identity
Who they are and how they operate.
- Invest across the full lifecycle from Pre-Seed to Growth and crossover/public opportunities
- Lead rounds in breakthrough healthcare companies, especially where OrbiMed can shape governance and strategy
- Use multiple capital formats—equity, private credit, and royalty financing—based on company maturity and risk profile
- Concentrate on four core healthcare verticals: biopharma, medical devices, diagnostics/tools, and tech-enabled services
- Scale exposure over time as clinical, regulatory, and commercial milestones reduce risk
Firm identity
Investment focus
Industries, themes, and typical ARR expectations.
Industries
Investment themes
Typical check by stage
Typical ARR by stage
Investment thesis
Core beliefs and strategy behind their investing approach.
OrbiMed’s investment thesis is to back innovative, growth‑oriented healthcare companies across the full life‑cycle, pairing deep domain diligence with flexible capital to compound value as products de‑risk and scale. The firm invests globally – North America, Europe and Asia – in four main sub‑sectors: biopharmaceuticals, medical devices, diagnostics/tools and technology‑enabled healthcare services. It deploys three platforms – public equity, private equity/venture and private credit/royalty – and typically acts as a lead investor, offering equity, credit and royalty‑based financing from seed/incubation through later‑stage growth. In therapeutics and tools, OrbiMed targets scientifically novel, category‑defining programs with rigorous data, clear regulatory pathways and strong commercial rationale, often incubating companies and scaling its commitment through successive rounds. In diagnostics and digital health, the focus is on differentiated clinical utility, workflow integration and scalable go‑to‑market models. The firm’s Royalty & Credit platform provides non‑dilutive capital to commercial‑stage companies, emphasizing predictable cash flows. OrbiMed integrates material ESG considerations but does not let them dominate decisions, and it avoids categorical sector bans, allowing flexibility to pursue emerging scientific opportunities while maintaining discipline around data quality, governance and alignment. Check sizes can reach up to ~$250 M per company when multiple funds are leveraged.
Decision patterns
How they evaluate and make investment decisions.
OrbiMed invests when deep diligence uncovers high‑quality science coupled with a strong, credible management team capable of advancing category‑defining programs. The firm favors opportunities that demonstrate clear regulatory pathways, robust clinical or technical data, and scalable go‑to‑market models. In diagnostics and digital health, demonstrated clinical utility and workflow integration are paramount; in later‑stage growth or royalty/credit deals, predictable revenue streams and cash‑flow durability dominate. OrbiMed typically leads rounds, takes board seats, and may incubate companies, reflecting a bias toward influence where conviction is strong. Deal‑breakers include irreproducible data, ambiguous regulatory routes, weak governance, or misaligned incentives. ESG considerations are incorporated when financially material but never primary. The firm balances team versus market versus traction differently by stage: early therapeutics weigh team and data highest, mid‑stage tools weigh market validation and traction, while credit/royalty investments prioritize revenue stability.
Risk appetite
OrbiMed adopts a balanced but assertive risk profile. It is comfortable leading high‑risk, high‑reward seed and Series A rounds in breakthrough therapeutics and platforms, while simultaneously providing downside‑protected credit and royalty financing to mature, revenue‑generating companies. The firm typically leads investments, takes board seats, and scales capital as risk de‑rises, resulting in a barbell strategy that blends aggressive early‑stage exposure with more conservative credit‑focused exposure.
Notable investments
Key portfolio companies and why they fit the thesis.
- Odyssey TherapeuticsLeadNext-gen precision immunomodulators/oncology; large early-stage financing aligns with OrbiMed's biotech thesis and willingness to lead at formation.
- AbCelleraLeadAI-enabled antibody discovery platform; OrbiMed co-led the Series B to scale a differentiated discovery engine.
- Intellia TherapeuticsLeadCRISPR gene-editing pioneer; OrbiMed led the $70M Series B in September 2015 in a category-defining modality.
- EvozyneLeadGenerative AI for therapeutic protein design; co-led to back platform-scale innovation.
- Aspen NeuroscienceLeadAutologous cell therapy for Parkinson's; clinical-stage, high-need asset co-led by OrbiMed.
- Avenzo TherapeuticsLeadOncology pipeline with best-in-class potential; OrbiMed co-led the Series B.
- Sidewinder TherapeuticsLeadNext-gen bispecific ADCs; sole Series A investor, demonstrating OrbiMed's propensity to lead early biotech builds.
- Guardant HealthLeadLiquid-biopsy leader; OrbiMed led the $100M Series D in January 2016 as the company scaled precision oncology diagnostics.
- Pee SafeLeadConsumer health brand with strong ARR and profitability in India; fits OrbiMed's Asia strategy and tech-enabled health focus.
- AdcendoFirst-in-class ADC pipeline; OrbiMed participated alongside the lead investor, illustrating selective participation.
Co-invested with
Other firms in this catalog who've backed the same companies.
Partners
Full firm roster — key partners, partners, and the wider team.
Key partners
Carl L. Gordon
Managing Partner
OrbiMed
Carl L. Gordon is a Managing Partner at OrbiMed and leads the firm's private equity team.
Sven H. Borho
Managing Partner
OrbiMed
Sven H. Borho, CFA, is a founder and Managing Partner of OrbiMed. He heads the firm’s public equity team and manages OrbiMed’s public equity and hedge funds.
W. Carter Neild
Managing Partner
OrbiMed
W. Carter Neild is a Managing Partner at OrbiMed who joined the firm in 2002.
Sunny Sharma
Partner and Senior Managing Director, Asia Team
OrbiMed
Sunny Sharma is a Partner and Senior Managing Director on OrbiMed's Asia team.
Partners
Mark Jelley
Partner
OrbiMed
OrbiMed credit and royalty partner focused on healthcare structured finance.
Diyong Xu
Partner
OrbiMed
OrbiMed private equity partner investing across biotech, diagnostics, pharma and medical devices.
Girish Bakhru, CFA
Executive Director
OrbiMed
OrbiMed Asia public-equity executive focused on healthcare across India, Korea and China.
David Wang
Partner
OrbiMed
OrbiMed Asia Partner focused on Greater China healthcare investments.
Daniel Ying
Executive Director
OrbiMed
OrbiMed Asia Executive Director focused on pharma and biotech investments.
nancy Chang
Former Chairman and Senior Managing Director, Caduceus Asia Partners at OrbiMed Advisors
OrbiMed
Former OrbiMed Asia leader and Tanox co-founder with biotech operating and board experience.
Michael E.
Partner
OrbiMed
OrbiMed partner focused on structured finance and healthcare royalty investments.
Scotland Stevens
General Partner
OrbiMed
OrbiMed General Partner leading trading across regions, products and business units.
Ankesh Bhansali
Managing Director
OrbiMed
OrbiMed Asia Managing Director focused on healthcare private equity.
Dimitrios Weedon
Managing Director
OrbiMed
OrbiMed Managing Director focused on healthcare royalties and structured finance.
David Bonita
General Partner
OrbiMed
OrbiMed General Partner and physician-investor in healthcare and therapeutics.
JI WANG
Executive Director
OrbiMed
OrbiMed Asia executive director focused on venture and growth-stage healthcare investments.
Arun Sadhanandham
Managing Director
OrbiMed
OrbiMed Asia Managing Director investing in healthcare private equity.
Josh Golomb
Partner
OrbiMed
OrbiMed public-equity partner focused on biotech and pharmaceutical investing.
Dina Chaya
Partner
OrbiMed
OrbiMed private equity partner focused on healthcare venture and later-stage opportunities.
Stella XING, CFA
Managing Director
OrbiMed
Asia public-equity Managing Director leading OrbiMed's China healthcare research.
Carl Gordon
Managing Partner
OrbiMed
OrbiMed Managing Partner leading private equity and biotech company formation.
Carter Neild
Managing Partner
OrbiMed
OrbiMed Managing Partner focused on healthcare royalties and Asia private investments.
Sumona Chakraborty
Executive Director
OrbiMed
Asia private-equity investor at OrbiMed focused on healthcare growth investments.
Evan Caplan, MD
Partner
OrbiMed
OrbiMed venture partner investing in therapeutics, medtech, healthtech and healthcare services.
Geoffrey Hsu
General Partner
OrbiMed
OrbiMed general partner and public-equity portfolio manager focused on biotech and emerging markets.
Peter Thompson
General Partner
OrbiMed
OrbiMed General Partner and biotech company-builder with board and operating experience.
Lars Enstrom
Managing Director
OrbiMed
OrbiMed managing director focused on healthcare structured finance and royalty investments.
Mona Ashiya
General Partner
OrbiMed
OrbiMed General Partner focused on biotech venture and special situations investments.
Team
Lizzie Speyer
Senior Associate
OrbiMed
OrbiMed senior associate focused on tools, diagnostics, and pharma services.
Jessica Zhang
Senior Associate
OrbiMed
Senior Associate focused on biotech private equity and venture investing.
Clay Daniel DeMarcus
Principal
OrbiMed
Principal focused on medical technology and non-therapeutics venture investing.
Vivek Sivathanu PhD
Principal
OrbiMed
OrbiMed Principal focused on healthcare private equity, with biotech research and biopharma strategy experience.
Roy Amariglio
Principal
OrbiMed
OrbiMed Principal investing across biotech, devices, and diagnostics.
Aditya Tolia
Private Equity Senior Analyst
OrbiMed
Private Equity Senior Analyst at OrbiMed with prior Investec and PwC banking experience.
Nathan Malewicki
Senior Associate
OrbiMed
Senior Associate at OrbiMed in New York.
Nate Yee
Principal
OrbiMed
Principal on OrbiMed's Credit and Royalty team.
Susnata Bhowmick
OrbiMed
Private equity professional with ICICI Venture public-profile history.
Ran Geng
Principal
OrbiMed
OrbiMed Principal focused on biotech venture investing.
Kipyegon Kitur
Principal
OrbiMed
OrbiMed private equity principal with BCG healthcare and pharmacology background.
Jonathan Wang
Senior Associate
OrbiMed
Senior Associate at OrbiMed China.
Will Sawyer
Senior Analyst - Specialty Pharmaceuticals
OrbiMed
OrbiMed senior analyst focused on specialty pharmaceuticals.
Ryan Moran
Senior Associate
OrbiMed
Senior Associate on OrbiMed's credit and royalty side.
应大为
Executive Director
OrbiMed
OrbiMed Asia Executive Director focused on pharmaceutical and biotech investments.
Cooper Steputis
Private Equity / Venture Capital
OrbiMed
Healthcare private equity and venture investor with prior investment banking experience.
Jiarun Qu
OrbiMed
Biotech and BioAI investor/operator with BioMap, Baidu Venture and GL Capital experience.
Elizabeth Krane
Senior Analyst
OrbiMed
Senior Analyst on OrbiMed's Public Equity team covering healthcare investments.
Kamran Elahi
Senior Associate
OrbiMed
OrbiMed private equity senior associate and former BofA healthcare banker.
Tyler Dunham
Senior Associate
OrbiMed
Senior Associate at OrbiMed in New York.
MJ Bhuller
Principal
OrbiMed
OrbiMed credit and royalty principal with healthcare credit investing experience.
Marianna Breland
Senior Associate
OrbiMed
Senior Associate at OrbiMed in New York.
Madeline Huber
Vice President
OrbiMed
OrbiMed private equity vice president with molecular biology training.
Emily Kalenik
Vice President
OrbiMed
Vice President focused on structured finance and healthcare royalty investments.
Alexis Megibow
Private Equity Associate
OrbiMed
Private Equity Associate at OrbiMed.
Emma Caress
Healthcare Investor
OrbiMed
Healthcare investor at OrbiMed.
Zack Mager
Vice President
OrbiMed
OrbiMed investor services VP with prior Centerbridge and Morgan Stanley experience.
Jonathan Mandelbaum
Principal
OrbiMed
OrbiMed private equity principal focused on biopharma company creation.
Brendan Weber, CFA
Principal
OrbiMed
Principal on OrbiMed's Credit & Royalty team focused on structured credit and royalty financings.
Lauren Ralph
Senior Associate
OrbiMed
OrbiMed private equity senior associate focused on life sciences and devices.
Natasha Shervani
Vice President
OrbiMed
OrbiMed VP investing in therapeutics and medical devices.
Public voice
Notable statements and public positions.
- "Over 90% of Fund V's committed capital is from existing, long‑standing firm relationships," said Carter Neild, Managing Partner (Aug 4 2025).
- "OrbiMed believes that there is a high congruence between companies that seek to act responsibly and those that succeed in building long‑term shareholder value," – OrbiMed Responsible Investing Policy.
- "We conduct deep due diligence on both the science and the management team. We look for companies developing something truly innovative—programs that can change the course of medicine," said Carl Gordon, Managing Partner.
Similar firms
Firms with overlapping stage and industry focus.
F-Prime
0.2%
Khosla Ventures
3.0%
B Capital
0.2%